Research Report: The Regulatory Role of ROR2 in Pancreatic Cancer Cell Plasticity Background Introduction Pancreatic ductal adenocarcinoma (PDAC) is a deadly disease with most patients lacking the possibility of a cure. This is partly due to the difficulty in early detection. One of the characteristics of PDAC is its extensive tumor cell heterogene...
The Role of IL-33 in Promoting Tumor Growth in Pancreatic Cancer Tissue and its Potential as a Therapeutic Target Background Introduction Pancreatic Cancer (PDA) is one of the most lethal malignancies worldwide, characterized by rapid clinical progression and poor treatment responses, with a five-year survival rate of only 13%. In the United States...
ZNF397 Deficiency Triggers TET2-Driven Lineage Plasticity and AR-Targeted Therapy Resistance in Prostate Cancer Academic Background and Research Motivation Existing research evidence suggests that cancer cell lineage plasticity and epigenetic reprogramming enable them to evade lineage-dependent targeted therapy by adopting lineage plasticity. Howev...
The Costimulatory Role of CD28 Enhances the Function of CAR-NK Cells through the LCK/CD3ζ/ZAP70 Signaling Axis Research Background and Objective Chimeric Antigen Receptor (CAR) T-cell therapy has shown significant effects in treating certain advanced cancer patients. However, CAR-T cell therapy has many limitations, such as high cost, complex prepa...
CRISPR-Dependent Screening in Primary Hematopoietic Stem Cells Identifies KDM3B as Specific Susceptibility for IDH2 and TET2 Mutant Genotypes Background and Significance Clonal Hematopoiesis (CH) refers to the abnormal growth of genetically distinct subclones of cells initiated by specific mutations in Hematopoietic Stem Cells (HSCs). This phenomen...
Mechanisms of Resistance to Carcinogenic KRAS Inhibition in Pancreatic Cancer Background Pancreatic Ductal Adenocarcinoma (PDAC) is a highly lethal disease. Most patients are diagnosed at an advanced stage and typically die within 12 months, primarily due to limited treatment options and poor response to standard chemotherapy. KRAS is the most crit...
This is an academic paper report on the study of acute myeloid leukemia (AML) stem cells. The study found that venetoclax treatment targeting the BCL-2 protein induces different mitochondrial calcium signaling changes in drug-sensitive and drug-resistant AML stem cells, thereby affecting their oxidative phosphorylation metabolism and survival. The ...
Response and Resistance Mechanisms of RAS Inhibitors in KRAS-Mutant NSCLC Research Background With the clinical development of RAS inhibitors, the treatment of KRAS-mutant Non-Small Cell Lung Cancer (NSCLC) faces a new turning point. However, in clinical practice, patients show poor long-term responses to RAS inhibitors, influencing clinical effica...
This study reveals a new targetable cancer subtype characterized by activating point mutations in the MET tyrosine kinase domain (TKD). Researchers identified MET TKD activating mutations in approximately 0.5% of patients across a genomic data set of over 600,000 cancer cases, encompassing various tumor types, with the highest prevalence in renal c...
Iron (Ferric Ion, Fe3+)-Dependent Telomerase Reactivation Drives Colorectal Cancer Development I. Research Background Colorectal Cancer (CRC) is the third most common cancer globally, involving both genetic and non-genetic factors in its pathogenesis. Existing research shows a significant association between high iron content, hereditary iron overl...